[Specific immunotherapies in the treatment of cancers].

Les immunothérapies spécifiques dans le traitement des cancers.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 25 10 2018
revised: 06 12 2018
accepted: 16 12 2018
pubmed: 15 1 2019
medline: 5 2 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

The offer of anti-cancer drugs has recently been disrupted by the introduction of checkpoint inhibitors on the market. Currently, one anti-CTLA-4, two anti-PD-1 and two anti-PD-L1 are authorized in the European Union, in seven different types of cancer. The clinical development of these therapies is still in full swing: in July 2017, more than 1 500 clinical trials were evaluating anti-PD-1, anti-PD-L1 and anti-CTLA-4 drugs in about twenty different locations and this number continues to increase. In the short term in France, other immunotherapies, the CAR-T cells, will complete this therapeutic arsenal. These immunotherapies appear as a real revolution in the treatment of some cancers. Nevertheless, many issues are associated with these therapies, particularly regarding the identification of good responders, the proper use of these drugs including the management of therapeutic strategies and safety profile, as well as the organization of care. In addition, the expenses associated with ipilimumab, nivolumab and pembrolizumab are substantial and almost tripled in one year, going from 120 million euros in 2015 to more than 340 million euros in 2016. This raises the question of the ability of the current healthcare system to maintain equitable access to innovation and best treatments for all patients. For all these reasons, the French National Cancer Institute decided to dedicate its thematic annual report on these innovative immunotherapies, targeting in particular checkpoint inhibitors and CAR-T cells, in order to produce an inventory of current data and an analysis regarding the different issues associated with these therapies.

Identifiants

pubmed: 30638899
pii: S0007-4551(18)30407-7
doi: 10.1016/j.bulcan.2018.12.007
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
B7-H1 Antigen 0
CD274 protein, human 0
CTLA-4 Antigen 0
CTLA4 protein, human 0
Ipilimumab 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0
Receptors, Chimeric Antigen 0
Nivolumab 31YO63LBSN
pembrolizumab DPT0O3T46P

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

37-47

Informations de copyright

Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Hélène Denis (H)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France. Electronic address: hdenis@institutcancer.fr.

Claire Davoine (C)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Elisabeth Bermudez (E)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Ghislain Grosjean (G)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Manon Schwager (M)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Norbert Ifrah (N)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Muriel Dahan (M)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Sophie Negellen (S)

Institut national du cancer (INCa), 52, avenue André-Morizet, 92513 Boulogne-Billancourt cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH